Some triptans are a more effective treatment for acute migraines than newer, more expensive drugs, finds an analysis of the latest evidence published by The BMJ.
Triptans work by narrowing blood vessels in the brain and preventing the release of chemicals that cause pain and inflammation.
The findings show that four triptans – eletriptan, rizatriptan, sumatriptan, and zolmitriptan – were better at relieving migraine pain than the recently marketed and more expensive drugs lasmiditan, rimegepant, and ubrogepant, which were comparable to paracetamol and most anti-inflammatory painkillers (NSAIDs).
Some triptans are a more effective treatment for acute migraines than newer, more expensive drugs, finds an analysis of the latest evidence published by The BMJ.
Triptans work by narrowing blood vessels in the brain and preventing the release of chemicals that cause pain and inflammation.
The findings show that four triptans – eletriptan, rizatriptan, sumatriptan, and zolmitriptan – were better at relieving migraine pain than the recently marketed and more expensive drugs lasmiditan, rimegepant, and ubrogepant, which were comparable to paracetamol and most anti-inflammatory painkillers (NSAIDs).
